tbuckley/cabot-search huggingface dataset:
Clinical outcomes after intensive VDT-PACE therapy for relapsed multiple myeloma.
Authors: Preet Paul Singh, Wilson I. Gonsalves, Vinay Gupta, Francis Buadi, Martha Lacy, Angela Dispenzieri, Morie Gertz, Suzanne R. Hayman, David Dingli, Stephen J. Russell, John Anthony Lust, Steven R. Zeldenrust, Prashant Kapoor, Arleigh Robertson McCurdy, S. Vincent Rajkumar, Shaji Kumar
Journal: Journal of Clinical Oncology (2013)

8600 Background: The combination of bortezomib, dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide and etoposide (VDTPACE) was developed as an intense regimen for disease control prior to tandem transplantation for multiple myeloma (MM) in total therapy protocols. The regimen is very effective in this setting, and since has also been used in the relapsed setting. We examined the outcomes of a set of patients undergoing VDTPACE therapy for relapsed MM at our institution. Methods: We identified 71 patients who received VDTPACE for relapsed MM, at Mayo Clinic from 7/2006 to 7/2012. Plasma cell leukemia was excluded. All data was extracted from clinical records. Results: The median age of patients was 59 years (range, 39-80); 48 (67.6%) were male. The median time from diagnosis to initiation of VDTPACE was 38.2 months (range, 2-125). The median number of cycles given was 1 (range, 1-9). The overall response rate after one cycle was 57.1% (14.3% VGPR, 22.2% PR and 20.6% MR) in the 63 patients in whom the response was evaluable. The median overall survival (OS) post-VDTPACE was 8.2 months (95% CI, 5.7-10.9). Eighteen (25.4%) patients went on to autologous stem cell transplantation (SCT), and 7 (9.9%) received matched allogeneic SCT following VDTPACE, and the median OS post-VDTPACE was significantly longer for these groups compared to those who were not transplanted (15.3 and 20.5 months, respectively vs 5 months, p-value &lt;0.001). Thirty eight of 66 (57.6%) patients were rehospitalized after initial admission for infusion therapy for a median duration of 6 days (range, 1-26). The median platelet and red cell transfusions were 4 (range, 0-21) and 5 (range, 0-22) units, respectively. Renal toxicity was seen in 13/62 (21%) patients and 27/65 (41.5%) patients developed neutropenic fever. The median duration to absolute neutrophil and platelet count recovery was 18 (range 12-42) and 27 (range, 12-42) days, respectively. Three (4.2%) patients died within 30 days and 11 (15.5%) within 8 weeks of initiating VDTPACE. Conclusions: VDTPACE is an effective therapy in relapsed MM but is associated with significant morbidity and short-term mortality. It appears to be more effective when followed by an autologous or allogeneic SCT.
Post-diagnosis BMI and physical activity in association with triple-negative breast cancer prognosis: Results from 5 prospective cohorts.
Authors: Sarah Jean Nechuta, Bette J. Caan, Wendy Y. Chen, Miriam Dwek, Min Gao, Shirley Flatt, Elizabeth Poole, Ruth E. Patterson, John P. Pierce, Claire Robertson, Ruth Swann, Wei Zheng, Xiao-Ou Shu
Journal: Journal of Clinical Oncology (2015)

1507 Background: Triple negative breast cancer (TNBC), defined as ER-/PR-/HER2-, has a poor prognosis and limited targeted treatment options. Modifiable lifestyle factors, including body mass index...
Human orf complicated by epidermolysis bullosa acquisita
Authors: E. Zuelgaray, C. Salle de Chou, J. Gottlieb, M. Battistella, M.D. Vignon-Pennamen, M. Bagot, F. Guibal, J.D. Bouaziz
Journal: British Journal of Dermatology (2017)

Orf is a DNA parapoxvirus transmitted to humans by contact with infected goats and sheep. Many complications have been reported after orf infection, including erythema multiforme. A few cases of autoimmune bullous dermatosis complicating orf disease have been reported to date. They are usually characterized by tense blister eruptions with or without mucosal involvement; linear deposition of C3, IgG and/or IgA along the basement membrane; and negativity of indirect immunofluorescence analysis and enzyme-linked immunosorbent assay (ELISA) (performed in four of 11 reported cases). These analyses have targeted antigens of bullous pemphigoid, mucous membrane pemphigoid or epidermolysis bullosa acquisita, except one case of mucosal pemphigoid with antilaminin-332 antibodies. We describe the case of a patient who presented with an ulceration on his finger 10 days after direct contact with a lamb during Eid al-Adha. Four weeks later he developed a severe tense blistering eruption associated with mucous membrane erosions. Indirect immunofluorescence analysis using the patient's serum revealed circulating antibasement membrane IgG that bound the dermal side of salt-split skin. ELISA was positive for recombinant immunodominant NC1 domain of type VII collagen. We finally diagnosed epidermolysis bullosa acquisita complicating probable human orf infection.
T-cell therapy in metastatic melanoma: TIL 1383I TCR transduced T cells after infusion and activity in vivo.
Authors: Courtney Regan, Joseph Clark, Tamson Moore, Kelly Moxley, Gina Scurti, Ann Lau Clark, Boro Dropulic, Heather Embree, Keisuke Shirai, Elizabeth Garrett-Mayer, Mingli Li, Kristen Tobin Vealey, Jonathan M. Eby, Caroline Le Poole, Michael Nishimura
Journal: Journal of Clinical Oncology (2015)

3043 Background: Studies in adoptive T-cell transfer have suggested that persistence of the transduced T-cells is central to the viability of this therapeutic option. The objectives of this phase I clinical trial using TCR TIL 1383I transduced T cells in stage IV melanoma patients include measuring of persistence and monitoring the behavior of tumor-reactive T-cells in vivo. Methods: Peripheral blood mononuclear cells (PBMCs) were isolated from three melanoma patients, activated with anti-hCD3 with rhIL2 and rhIL15, transduced with lentivirus encoding the TIL 1383I TCR, and expanded to treatment numbers. The transduced cells were suspended in 5% human albumin and infused over 30 minutes. The infusion was preceded by lymphodepletion with fludarabine and cyclophosphamide and followed with low dose IL-2 for one week. A modified CD34 cassette in the vector enabled monitoring of the transduced T cells in the patient’s PBMC post-infusion. PBMCs were collected from patients on days 1, 3, 5, 7, 14, 25, 35 and monthly up to 3 months and then every 1-3 months as clinically indicated. The presence of transduced T-cells at each time point was measured by staining with anti-CD34 mAb and analyzed using a BD LSRFortessa flow cytometer. Results: Transduced T-cells were detected in the blood of all three patients post infusion. Clinical activity was demonstrated in two patients – one in the form of tumor shrinkage and another with development of progressive vitiligo. Conclusions: Previous studies with TIL suggest better T-cell engraftment, persistence, and therapeutic efficacy with homeostatic proliferation after lymphodepletion. Out results confirm that the infused TIL 1383I TCR transduced T-cells could be detected up to 6 months after infusion and demonstrate activity. Clinical trial information: NCT01586403.
Triple negative breast cancer: An institutional review
Authors: M. Dioca, M. Savignano, L. Gimenez, L. Marino, C. Delfino, A. M. Alvarez, E. Mickiewicz
Journal: Journal of Clinical Oncology (2009)

e22214 Background: Triple negative breast cancer (BC) is a distinct group of tumors that show common but heterogeneous morphologic, genetic, and immunophenotypic features. Despite differences in the definition and prevalence, it comprises 8% to 20% of all breast cancers and is associated with an aggressive clinical course with significant risk of either local or systemic relapse and subsequent increased risk of death on short term follow up (particularly in the first 5 years).We study the pathological characteristics and the clinical outcome of a cohort of 77 triple negative BC patients (pts) diagnosed at our Institution. Methods: Between January 1999 and September 2008, 77 (stage I to III) triple negative BC pts. were retrospectively analyzed. All pts had their receptor status, Her neu, ck-5, ck-6 and staining for EGFR by the same pathologist. Pathological parameters (Pp) analyzed were: status of axilary lymph nodes (LN), nuclear grade, histologic grade, mitotic index and vascular invasion and the use of antraciclins in the adjuvant setting. Univariate and multivariate analysis (proporcional hazard regression Cox model) for the Pp associated with relapse, and the log rank test to compare two curves of each Pp for disease free survival (DFS), and overall survival (OS) were performed. Results: The median age was 57.8 years (range 30–86 years).The median follow up time was 57.7 months (range, 4- 241). From 77 Pts. analized, 65 (84.4%) were basal-like and 43 (64.6%) of those were GH3. Stage at the time of presentation was: 16 (20,7%) stage I; 40 (51,9%) stage II; 21 (27,7%) stage III. Pre-menopausal status was 29,48% (23 pts.), and 61% (47 pts) were LN negative. Overall, relapse rate was 38.5 % (n= 30), 63 Pts (81.8%) are still alive. Median DFS was not reached. Global DFS and OS were 59% and 79% respectively, and status of LN was the only prognostic factor. LN- vs LN+ DFS (p&lt; 00.02) and OS p (&lt; 0.02).All others Pp analyzed were not statistically significative. Conclusions: Despite previous studies have demonstrated that triple negative is an independent marker of poor prognosis in BC as a whole, in the LN-negative, and LN-positive groups, in this basal like population only positive LN was an independent poor prognostic factor for DFS and OS. No significant financial relationships to disclose.
Prognosic value of lower uterine segment involvement in high-grade endometrial cancers.
Authors: Paola A. Gehrig, Leslie Horn Clark, Jason Franasiak, Victoria Lin Bae-Jump, Emily Ko
Journal: Journal of Clinical Oncology (2012)

5092 Background: To determine the relationship of lower uterine segment (LUS) involvement and clinical-pathologic outcomes in high grade endometrial cancers (EC). Although LUS and prognosis has been previously reported in the literature, the results have been conflicting and limited to early stage cases without focus upon the highest risk histologies. Methods: A single-institution retrospective cohort analysis of all grade 3 EC from Jan 2005- Sept 2010 was performed. Clinical-pathologic data were abstracted. LUS status was determined based on permanent-section pathology. Statistical analyses were performed using univariate and bivariate analyses with t-tests, X2, and log-rank tests. Multivariate regressions were performed by cox modeling. Two sided p-values&lt;0.05 were considered significant. Results: Of 329 cases, 52% were LUS+. Mean age was 66.1(SD 10.8) and BMI 31.7(SD 8.3). The majority were Caucasian (63.2%) and 30.1% were African-American (AA). Most women (80.2%) were overweight or obese, 58.7% had hypertension, and 22.5% were diabetic. Most women had stage I disease (54.8%), but 8.6% had stage II disease, and 36.6% had stage III-IV disease. Histologic subtypes included 32.2% endometrioid, 47.4% serous/clear cell, and 17% carcinosarcoma. Thirty-nine percent had &gt; 50% myometrial invasion (MI) and 43.2% had LVSI. Most of the women (80.8%) underwent retroperitoneal node dissection (77.9% pelvic, 70.0% periaortic). Mean follow-up time was 24.5 months (range 0.13, 73.3). Age, HTN, and DM did not differ by LUS status. Statistically significant factors associated with LUS positivity included race AA (38.3 v 26.5%), obesity (57.5 v 46.7%), serous/clear cell (65.7 v 53.8%), LVSI (56.2 v 30.5%), deep MI (52.1 v 25.3%), and positive nodes (42.4 v 12.7%). LUS+ was significantly associated with an increased rate of recurrence (HR 2.3, CI 1.16-4.47, p =0.02) after adjusting for obesity, deep MI, LVSI, nodal status, stage, serous/clear cell histology, and adjuvant therapy. Conclusions: Lower uterine segment was independently associated with an increased rate of recurrence in high grade EC. This should be confirmed in prospective endometrial trials to see if this remains an independent predictor of recurrence.
The impact of Australia Asia Pacific Clinical Oncology Research Development (ACORD) on research productivity of participants according to region of origin
Authors: B. Koczwara, S. Ackland, A. Esterman, F. Marine, M. Stockler, I. Olver
Journal: Journal of Clinical Oncology (2007)

17074 Background: ACORD is a 1-week, intensive educational workshop designed to increase skills of junior cancer clinical researchers from the Asia Pacific region. Participants come from region of diverse cultures, languages and resources. Methods: We surveyed participants 1 year after the workshop to determine its impact on their research output. Participants were grouped into those from: Australia or New Zealand (ANZ), developed Asian countries (Japan, Korea, Taiwan), and developing Asian countries (India, China, Bangladesh, Philippines, Indonesia, Malaysia). Results: The response rate was higher from developed Asia (10/10, 100%), than ANZ (44/59, 75%) and developing Asia (7/12, 58%). The proportion of respondents spending more than half of their time in research was higher in ANZ (21%), than developing Asia (14%) or developed Asia (10%). The workshop was rated very valuable by more respondents from developing Asia (71%) than from ANZ (59%) and developed Asia (60%). More than half of respondents had submitted their ACORD protocol to an IRB. Progress activating protocols was reported more frequently by respondents from developing Asia (86%) than developed Asia (70%) and ANZ (59%). Involvement in other research was also reported more frequently by respondents from developing Asia (100%) than ANZ (82%) or developed Asia (80%). The most frequently reported barriers to progressing research were: other work commitments (71% for developing Asia, 44% for ANZ, 30% for developed Asia) and lack of funding (71% for developing Asia, 39% for ANZ, and 33% for developed Asia). Continuing contact with faculty and participants was reported more frequently by respondents from ANZ (59%), than developed Asia (43%) or developing Asia (30%). Conclusions: Respondents were highly satisfied with the workshop, perceiving positive effects on their research skills and careers. Participants from developing countries were more likely to take their protocols forward, despite reporting greater barriers to progress, and less continuing contact with faculty and participants. Protected time and support for researchers are worth considering for developing countries wanting to improve their research output. [Table: see text]
Carcinoma of the Esophagus
Authors: David P. Boyd, Herbert D. Adams, Ferdinand A. Salzman
Journal: New England Journal of Medicine (1958)

AN experience with 335 cases of carcinoma of the esophagus forms the background but not the basis for this report. Rather, it seems more reasonable to examine smaller successive groups of cases to reflect more accurately changing concepts in management. In 1953 a group of 161 cases was reported.1 Since that time we have had the opportunity to observe and treat an additional 174 patients with carcinoma of the esophagus. We wish at this time to review the latter group and pay particular attention to a smaller, more recent group that has had intensive treatment with 2,000,000-volt x-ray apparatus at . . .
Safety and efficacy of necitumumab continuation therapy: Subgroup analysis of phase 3 SQUIRE study.
Authors: Tudor E. Ciuleanu, Mark A. Socinski, Coleman K. Obasaju, Alexander Luft, Aleksandra Szczesna, Wojciech Szafranski, Rodryg Ramlau, Beatrix Bálint, Andrzej Kazarnowicz, Olivier Molinier, Henrik Depenbrock, Shivani Nanda, Luis Paz-Ares, Nick Thatcher
Journal: Journal of Clinical Oncology (2015)

e19024 Background: The SQUIRE study demonstrated that the addition of necitumumab (N) to gemcitabine-cisplatin (GC) improved survival in patients (pts) with stage IV sq-NSCLC. This retrospective analysis compares safety and efficacy outcomes for patients who received N single agent as continuation therapy after completion of chemotherapy treatment (CT) to the continuation therapy-eligible population of the GC arm. Methods: Pts were randomized 1:1 to GC (G = 1250 mg/m² iv, days 1 and 8; C = 75 mg/m² iv, day 1) plus N (800 mg iv, days 1 and 8) (GC+N arm), or GC alone (GC arm) every 21 days up to 6 cycles. Pts in GC+N with no progression continued on N alone until progressive disease or intolerable toxicity. We present overall survival (OS), progression-free survival (PFS), and safety (TEAEs) for pts in the GC+N arm who were alive and progression free at the start of N alone and pts in GC arm who were alive and progression free at the completion of CT. This analysis included pts in both arms who received at least 4 cycles of CT. Results: 261 pts were progression free and received ≥ 1 dose of N alone in GC+N arm. 215 pts in GC arm completed at least 4 cycles of CT and were progression free. Baseline characteristics were well balanced between GC+N and GC arms, respectively: median age was 62 yrs in both arms; males 81% vs 89%; whites 82% vs 85%; ECOG PS 0-1 94% vs 95%. Exposure to CT was balanced in both arms. Median OS from randomization in GC+N arm vs GC arm were: 15.9 vs 15 months (HR 0.85 [95% CI, 0.69, 1.05]; p = 0.139). Median PFS from randomization in GC+N vs GC pts were: 7.4 vs 6.9 months (HR 0.86 [95% CI, 0.70, 1.06], p = 0.150). Select TEAEs of relevance are shown in the table below. Conclusions: Pts alive and progression free after completion of CT had consistent treatment effect in favor of GC+N. Continuation with N alone did not result in any unexpected increases in adverse events. Clinical trial information: NCT00981058. CT Phase Continuation Phase GC+NN = 261% of Pts GCN = 215% of Pts NN = 261% of Pts Category Any Grade Grade ≥ 3 Any Grade Grade ≥ 3 AnyGrade Grade ≥ 3 Neutropenia 54.4 33.3 55.8 32.1 0.4 0.4 Hypomagnesemia 40.2 14.2 18.6 0.9 16.1 2.7 Rash 85.8 5.7 10.2 0.5 26.1 4.2 Arterial thromboembolic event 3.4 1.1 0.5 0 2.3 1.9 Venous thromboembolic event 7.3 2.3 4.2 0.9 2.7 1.9
Adherence rates to endocrine therapy among African American women with stage I-III, hormone receptor-positive breast cancer treated at Grady Memorial Hospital in Atlanta, Georgia.
Authors: Megan Jean McKee, Danny Nguyen, Seham Al Haddad, Elsa Paplomata, Marjorie Adams Curry, Yuan Liu, Ruth O'Regan, Amelia Bruce Zelnak
Journal: Journal of Clinical Oncology (2013)

e11582 Background: Breast cancer mortality has historically been higher in African American (AA) women compared to Caucasian women. Controlling for tumor characteristics, biological markers and comorbidities does not account for the disparity. Previous studies have shown that AA women are more likely to have a high 21-gene recurrence score compared to Caucasian women. Another potential variable affecting treatment outcomes is adherence to adjuvant endocrine therapy (ET). We conducted a retrospective review of pharmacy records at Grady Memorial Hospital (GMH) to examine the non-adherence rate among predominantly AA patients (pts). Methods: Pharmacy database records were examined for pts filling prescriptions for tamoxifen, anastrozole, or letrozole at GMH in Atlanta, Georgia from 2004-2009. Baseline characteristics were obtained by chart review. Pts were excluded if they had metastatic disease, DCIS, less than 60 days of eligible prescription, were male, deceased during the study period, benign disease, or no documentation of breast cancer in the electronic medical record (EMR). Non-adherence was defined as those filling less than 80% of eligible days covered by her prescription. Results: 679 pts were identified who filled prescriptions for tamoxifen, anastrozole, or letrozole at Grady pharmacy from 2004-2009. Pts who were excluded had metastatic disease (152), DCIS (101), had less than 60 days of eligible prescription (65), had no documentation of breast cancer in the EMR (25), were male (6), deceased before 2009 (5), or had benign disease (9). Of the 316 pts eligible for the study, median age was 60 (26 to 94) at time of diagnosis, 86% were AA, and 39% were node positive. 167 pts filled prescriptions for tamoxifen, 95 for anastrozole, and 54 for letrozole. The non-adherence rate for tamoxifen was 50%, anastrozole 38%, and letrozole 48%. Overall non-adherence rate was 46%. Conclusions: The overall non-adherence rate to adjuvant ET among a predominately AA population seen in a county hospital was similar to previously reported rates. Non-adherence to ET in this underserved AA pt population does not fully account for disparate outcomes.
Late effects among head and neck cancer survivors in Utah cancer survivorship study.
Authors: Daisuke Kawakita, Sarah Abdelaziz, Yuji Chen, Kerry G. Rowe, Yuan Wan, Vikrant Deshmukh, Michael Newman, Alison M Fraser, Ken R Smith, Marcus Monroe, Mia Hashibe
Journal: Journal of Clinical Oncology (2017)

137 Background: Sites of head and neck are associated with chewing, swallowing and speaking. As for treatment of head and neck cancer (HNC), we have to consider organ preservation as well as clinical outcomes. Although non-surgical treatments have been preferred in recent years, complications after treatment have been a concern. The aim of this study was to evaluate the late effects in a cohort of HNC survivors in Utah compared to a matched cohort of cancer free individuals. Methods: Up to 5 cancer free individuals were matched to each HNC survivor on birth year, sex, birth state, and follow up time. Electronic medical records and statewide ambulatory and inpatient surgery data were used to identify late effects over two time periods: 1-5 and 5-10 years after cancer diagnosis. Cox proportional hazards models were used to estimate the risks of late effects. We adjusted for matching factors, race and number of hospital visit. Results: In this study, 2,432 HNC survivors and 12,149 matched controls were enrolled. More than 80% cases had loco-regional disease and a histological type of squamous cell carcinoma. Hazard ratio (HR) for second primary HNC was notably increased among HNC survivors for both 1-5 years (HR: 1498.46; 95% confidence interval (CI), 158.58-14159.69) and 5-10 years (HR: 1509.62; 95% CI, 147.94-15404.15) post cancer diagnosis. And, HRs for respiratory disease, including respiratory system, lung cancer and pneumoniae, were also increased among HNC survivors for both 1-5 years and 5-10 years post cancer diagnosis. As for hearing loss, HNC survivors had a increased HR for 1-5 years post cancer diagnosis (HR: 5.90; 95% CI, 2.67-13.01) and this association was consistent for 5-10 years post cancer diagnosis (HR: 5.01; 95% CI, 2.06-12.18). Conclusions: In this study, we found HNC survivors have notable associations with second primary HNC, smoking related respiratory disease, and hearing loss which might be associated with chemotherapy when compared to cancer free subjects.
RUNX3 Expression Is an Independent Prognostic Factor in Cytogenetically Abnormal Adult Acute Myeloid Leukemia (AML) Patients with Wild-Type FLT3.
Authors: Tsz-Ki Kwan, Chi-Keung Cheng, Suk-Hang Cheng, Natalie P.H. Chan, Rosalina Ip, Raymond S.M. Wong, Sze-Fai Yip, Chi-Kong Li, Margaret H.L. Ng
Journal: Blood (2010)